Mount Sinai Sues CVS in Federal Court, Alleging $121 Million Fraud and Racketeering Scheme Involving 340B Drug Program

The Mount Sinai Health System has filed a federal lawsuit against CVS Health Corporation, accusing the pharmacy giant of executing a “secret pricing scheme” that diverted more than $121 million in federal drug discount funds intended for low-income and uninsured patients. Filed in the U.S. District Court for the Southern District of New York, the lawsuit alleges racketeering, fraud, and breach of contract, claiming CVS exploited its vast vertical integration to withhold critical financial support. CVS has declined to comment on the active litigation, stating it remains focused on business priorities, while health policy experts warn the case highlights systemic transparency issues within the federal 340B drug pricing program.

The Federal Lawsuit and Core Allegations

MANHATTAN, N.Y. — The Mount Sinai Health System filed a comprehensive lawsuit on Monday in Manhattan federal court against CVS Health Corporation, alleging that the pharmacy giant systematically diverted more than $121 million from a federal program designed to subsidize healthcare for low-income, uninsured, and under-insured patients.

According to the complaint, CVS utilized its dominant position in the pharmaceutical supply chain to intercept funds from the federal 340B Drug Pricing Program since 2020. The lawsuit levels severe charges against CVS, including violations of the Racketeer Influenced and Corrupt Organizations (RICO) Act, common law fraud, breach of contract, and unjust enrichment.

Mount Sinai contends that these actions directly harmed its charitable mission by starving the hospital system of resources required to treat New York’s most vulnerable populations. In its legal filing, the healthcare provider stated:

“[Mount Sinai] is entitled to receive discounts on drug costs from drug manufacturers, and channel the savings from those discounts to fund their charitable mission of providing quality medical care to those in need. These losses directly impact [Mount Sinai’s] funding and programs to provide clinical care to the poorest and most vulnerable patients – the intended beneficiaries of the 340B Program.”

When reached for comment regarding the specific allegations of fraud and contract termination, a spokesperson for CVS Health Corporation declined to address the specifics of the filing. In a brief statement, the company noted that it does not comment on ongoing litigation and “remains focused on serving our customers and executing our business priorities.”

Understanding the Mechanics of the 340B Program

To understand the legal dispute between Mount Sinai and CVS, it is necessary to examine the mechanics of the 340B Drug Pricing Program. Enacted by Congress in 1992, the 340B program requires pharmaceutical manufacturers to provide outpatient drugs to eligible healthcare organizations—known as “covered entities”—at significantly reduced prices. These covered entities generally include safety-net hospitals, clinics, and providers that serve a disproportionate share of low-income or rural patients.

Because many safety-net hospitals do not operate full-scale, in-house retail pharmacies capable of reaching all patients, the federal government allows them to contract with outside retail pharmacies, known as “contract pharmacies.” Under these agreements, the contract pharmacy (such as CVS) dispenses the discounted 340B drugs to the hospital’s patients.

The pharmacy collects payments from the patients or their insurance providers, receives reimbursements from government programs like Medicaid, and is then structurally required to pass the drug-manufacturer discounts back to the hospital, minus an agreed-upon administrative or dispensing fee.

The Alleged “Secret Pricing Scheme”

Mount Sinai’s legal team argues that CVS engineered a complex financial maneuver to retain these manufacturer discounts for itself rather than transferring them to the healthcare provider.

According to the complaint, CVS’s various subsidiaries receive an initial payment for prescribed medications directly from patients or from Mount Sinai. Concurrently, CVS seeks and receives reimbursement for those same medications from Medicaid. Mount Sinai argues that under the established 340B framework and their explicit contract, CVS was legally obligated to reimburse Mount Sinai for the exact difference between the drug’s actual discounted cost and its adjusted cost after CVS was made whole by Medicaid.

Instead, Mount Sinai alleges that CVS pocketed this financial margin. The suit claims CVS successfully obscured this practice by exploiting its extensive vertical integration. Over the past two decades, CVS has expanded far beyond traditional retail pharmacies, acquiring the health insurance provider Aetna and the major pharmacy benefit manager (PBM) Caremark.

Mount Sinai argues that because all the internal entities responsible for auditing, reviewing, and approving these transaction determinations are owned by CVS, the company could make “improper” financial calculations in secret. The filing alleges that CVS routinely withheld clear documentation regarding when it received Medicaid reimbursements, the specific amounts of those reimbursements, or which precise prescriptions fell under the 340B program criteria.

The legal complaint summarizes this behavior in sharp terms:

“The largest and most sophisticated for-profit [pharmacies] … realize substantial profits by looting a federal drug pricing program designed to aid non-profit 340B providers caring for the most resource-strapped and vulnerable patients. [CVS’s] fraudulent, unlawful and deceptive practices have harmed [Mount Sinai] by taking millions of dollars that were supposed to flow to [Mount Sinai] to fund the provision of charitable and free medical care to the uninsured and under-insured.”

Contract Disputes and Escalation

The friction between the two organizations escalated significantly before the filing of the lawsuit. Mount Sinai states that when its internal financial analysts noticed discrepancies and confronted CVS regarding the missing allocations, the pharmacy chain refused to cooperate.

According to the contract governing their 340B relationship, Mount Sinai maintained the legal right to audit CVS’s internal financial records to verify compliance. The lawsuit claims that CVS explicitly denied Mount Sinai access to these ledger records.

Furthermore, Mount Sinai alleges that when it continued to push for financial transparency and a formal audit, CVS responded by unilaterally terminating the contract entirely. Mount Sinai contends that this termination was a retaliatory measure designed to conceal the alleged fraud, which ultimately disrupted the hospital’s logistics, hindered its ability to efficiently distribute essential medications to patients, and severely impacted its indigent care fund.

Broader Political Landscape and Policy Implications

This legal battle unfolds amidst a broader, highly contentious national debate regarding the oversight and scale of the 340B program. In recent years, the program has grown exponentially, drawing intense scrutiny from pharmaceutical manufacturers, healthcare trade groups, and federal lawmakers.

+------------------------------------------------------------------------+
|                      340B Program Stakeholder Views                    |
+------------------------------------+-----------------------------------+
| Safety-Net Hospitals & Providers   | For-Profit Pharmacies & PBMs      |
+------------------------------------+-----------------------------------+
| Rely on drug discounts to subsidize| Argue they provide necessary      |
| non-reimbursed care, emergency     | infrastructure and deserve fair   |
| services, and clinics for the poor.| compensation for dispensing risks.|
+------------------------------------+-----------------------------------+

Nonprofit hospital advocacy groups, such as the American Hospital Association (AHA), argue that 340B savings are vital lifelines that allow safety-net providers to keep emergency rooms open, operate clinics in underserved neighborhoods, and offer free or heavily subsidized care. They maintain that for-profit corporations are increasingly siphoning off these benefits.

Conversely, trade groups representing pharmaceutical manufacturers and PBMs have lobbied Congress for stricter regulations, alleging that the 340B program has grown beyond its original legislative intent. They argue that many hospitals do not transparently track whether the savings are passed directly to patients at the pharmacy counter, claiming the program has turned into a revenue generator for well-capitalized hospital systems.

This federal lawsuit highlights a different structural vulnerability: the immense power of vertically integrated corporate pharmacies over non-profit hospital networks. If Mount Sinai’s claims are validated by the court, it could spark widespread demands for federal regulatory intervention and enhanced transparency mandates for contract pharmacies operating within the 340B ecosystem.

In its final prayer for relief, Mount Sinai is asking the Manhattan federal court to intervene by forcing CVS to reenter the 340B contract agreement, issuing a permanent injunction to end the practice of withholding federal program funds, and awarding Mount Sinai treble damages—amounting to three times the $121 million it alleges was unlawfully withheld.